NEW YORK (GenomeWeb) – Scandinavian private equity firm Summa Equity said today that it has acquired Swedish life science firm Olink Proteomics.
According to the companies, Summa plans through the acquisition to help Olink scale its business globally. Based out of Uppsala, Sweden, Olink also maintains a US office and laboratory in Watertown, Massachusetts.
Founded in 2004 as a spinout from the lab of Uppsala University researcher Ulf Landegren, Olink is perhaps best known for its proximity extension assay (PEA) technology, which allows for highly sensitive, highly multiplexed protein measurements.
"The scientific and business opportunities for Olink Proteomics are enormous, as its technology is radically transforming the market for proteomics, thus enabling improved patient treatment," Tommi Unkuri, partner at Summa Equity, said in a statement. "We look forward to supporting the company in its ambition to continue investing in improved customer solutions, and its effort to roll out its technology on a worldwide basis."
Summa will be the majority shareholder in Olink, with the existing management team and Landegren remaining as shareholders.
Financial and other terms of the deal were not disclosed.